miR-195 Has a Potential to Treat Ischemic and Hemorrhagic Stroke through Neurovascular Protection and Neurogenesis

miR-195 Has a Potential to Treat Ischemic and Hemorrhagic Stroke through Neurovascular Protection and Neurogenesis

Tissue plasminogen activator is the only U.S. FDA-approved therapy for ischemic stroke, while there is no specific medication for hemorrhagic stroke. Therefore, the treatment of acute stroke continues to be a major unmet clinical need. We explored the effects of miR-195 on neurovascular protection a...

Full description

Bibliographic Details
Main Authors: Hsin-Yun Cheng, Yung-Song Wang, Po-Yuan Hsu, Chien-Yuan Chen, Yi-Chu Liao, Suh-Hang H. Juo
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050119300026

Similar Items

Similar Items